fasudil has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guerra, FS | 1 |
| Oliveira, RG | 1 |
| Fraga, CAM | 1 |
| Mermelstein, CDS | 1 |
| Fernandes, PD | 1 |
1 other study available for fasudil and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; beta Catenin; Carcinoma; Cell | 2017 |